More Drugmakers To Join Glaxo Effort To Disclose Trial Data

In yet another bid to respond to calls for greater disclosure of clinical trial data, several other drugmakers next month are expected to join to a web site that was recently launched by GlaxoSmithKline in order to satisfy the clamor for wider access to detailed study data. “Our aim is to progress to becoming an independent (portal) that accommodates multiple partners,” said Perry Nisen, who is a senior vp for science and innovation at Glaxo. “This is a start – a step in what we hope will be widespread movement to provide research data for clinical trials as well as other sources of clinical and health-related data.” Among those that have agreed to participate is Roche, although its involvement had actually been disclosed several months ago (this is the site). The other companies were not named, but he indicated a half dozen are expected to become involved. Nisen made his remarks while speaking at a conference on clinical trial data sharing and transparency that was held yesterday at the Harvard School of Public Health. The Glaxo site, you may recall, is supposed to make available patient-level data from its clinical trials to independent researchers. This means that other scientists will have an opportunity to study the material and develop their own findings about safety and effectiveness. This also includes data for discontinued drugs. The drugmaker has created a separate panel to review requests. The move came after years of controversy over the extent to which ...
Source: Pharmalot - Category: Pharma Commentators Authors: Source Type: blogs